Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenformin SCHEMBL10325620 | 1.00 | LMNA (1.00) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| Phenformin SCHEMBL8425 | 1.00 | LMNA (1.00) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| Phenformin SCHEMBL787929 | 0.96 | LMNA (0.93) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| SCHEMBL19770321 | 0.85 | HIF1A (0.74) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| SCHEMBL28524333 | 0.85 | HIF1A (0.74) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| [11C]Phenethylguanidine SCHEMBL837645 | 0.84 | HTR3A (0.80) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| SCHEMBL23366564 | 0.81 | TSHR (0.69) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| SCHEMBL1736064 | 0.80 | TAAR1 (0.67) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| SCHEMBL1736065 | 0.80 | TAAR1 (0.67) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| [11C]Phenethylguanidine SCHEMBL28305963 | 0.78 | HTR3A (0.71) | LMNAHIF1ATSHRSLC22A2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025108865-A1 | HERBICIDAL COMPOSITIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-30 | — | — | WO | claimed |
| WO-2025235276-A1 | COMBINATION OF IL-1 RECEPTOR INHIBITORS, ANTI PD-1, AND IL-4 INHIBITORS IN THE TREATMENT OF CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250297321-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | disclosed |
| US-20250073167-A1 | A POLYMER TO INCREASE THE BIOAVAILABILITY OF A PHARMACEUTICAL COMPOUND | CATALYA (BE) | 2025-03-06 | — | — | US | disclosed |
| US-20240374740-A1 | POLY AMPHIPHILIC COMPLEXES FOR THE DELIVERY OF A HYDROPHOBIC ACTIVE AGENT, COMPOSITIONS AND METHODS | Université de Liège (BE) | 2024-11-14 | — | — | US | disclosed |
| US-12031137-B2 | Compositions comprising SASP modulators and senescence attenuators and uses thereof for modulating cellular senescence | RSEM, LIMITED PARTNERSHIP (CA) | 2024-07-09 | — | — | US | disclosed |
| WO-2024097756-A1 | INTERRUPTED RAN PROTEINS IN DISEASE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023209215-A1 | BROAD-SPECTRUM ANTIVIRAL AGENT | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2023-11-02 | — | — | WO | disclosed |
| EP-4268810-A1 | BROAD-SPECTRUM ANTIVIRAL AGENT COMPRISING PHENFORMIN | Eberhard Karls Universität Tübingen, Medizinische Fakultät (DE) | 2023-11-01 | — | — | EP | disclosed |
| CN-110023332-B | Compositions comprising SASP modulators and senescence attenuating agents and use thereof for modulating cellular senescence | RSEM有限合伙公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20110269764-A1 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF SYNAPSE FUNCTION | PHARNEXT (FR) | 2011-11-03 | — | — | US | disclosed |
| EP-2322163-A1 | New therapeutics approaches for treating alzheimer disease | Pharnext (FR) | 2011-05-18 | — | — | EP | disclosed |
| CN-102065898-A | Novel therapeutic approaches for treating alzheimer's disease and related disorders by modulating angiogenesis | PHARNEXT | 2011-05-18 | — | — | CN | disclosed |
| CN-102065858-A | Combination compositions for treating alzheimer's disease and related conditions using zonisamide and acamprosate | PHARNEXT | 2011-05-18 | — | — | CN | disclosed |
| CN-102065897-A | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response | PHARNEXT | 2011-05-18 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2009127251-A1 | COMBINATIONS COMPRISING A RENIN INHIBITOR | NOVARTIS AG (CH) | 2009-10-22 | — | — | WO | disclosed |
| WO-2008141074-A1 | IDENTIFICATION OF COMPOUNDS THAT PROTECT AGAINST AMYLOID DISEASES | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20050014732-A1 | Combination of an aldosterone receptor antagonist and an anti-diabetic agent | PHARMACIA CORPORATION (US) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073167-A1 | A POLYMER TO INCREASE THE BIOAVAILABILITY OF A PHARMACEUTICAL COMPOUND | PGF, PIGS, UGT1A10 | LMNA 1507/4885HIF1A 207/4885TSHR 4272/4885 |
| US-20240374740-A1 | POLY AMPHIPHILIC COMPLEXES FOR THE DELIVERY OF A HYDROPHOBIC ACTIVE AGENT, COMPOSITIONS AND METHODS | ABCB11, NUP205, CHMP4B | LMNA 603/4885HIF1A 894/4885TSHR 2763/4885 |
| US-20050014732-A1 | Combination of an aldosterone receptor antagonist and an anti-diabetic agent | NR3C2, REN, AGTR1 | LMNA 2212/4885HIF1A 1824/4885TSHR 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.